Physician profile
Jeffery E Nelson
NPI 1285602128
$146,563.32
in general payments reported to CMS, 2019-2025
15 companies · $16.98 in 2025
The $16.98 reported for 2025 was less than what a typical Critical Care Medicine (Internal Medicine) provider received nationally (typical 2025 total: $189).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $195 · 2020: $124 · 2021: $21K · 2022: $59K · 2023: $49K · 2024: $16K · 2025: $16.98.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $56K · Travel and Lodging: $9,767 · Food and Beverage: $140.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $55,547.00 |
| Travel and Lodging | $9,766.80 |
| Food and Beverage | $140.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kedplasma LLC | $145,639.60 | 2021-2024 | |
| Amarin Pharma, INC. | $260.83 | 2019-2021 | |
| Novo Nordisk INC | $118.53 | 2022 | |
| Abbvie INC. | $109.94 | 2021-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $84.37 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $80.19 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $57.08 | 2019-2020 | |
| Glaxosmithkline, LLC. | $56.86 | 2023-2024 | Shingrix, Arexvy |
| Arbor Pharmaceuticals, INC. | $34.79 | 2019-2022 | |
| Almatica Pharma LLC | $31.68 | 2021-2023 | Gralise |
| Sanofi-Aventis U.S. LLC | $23.64 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $18.68 | 2021 | |
| Xeris Pharmaceuticals, INC. | $17.16 | 2024 | Gvoke Hypopen |
| Lilly USA, LLC | $16.98 | 2025 | Zepbound, Mounjaro |
| Amgen INC. | $12.99 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffery Nelson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.